What did @grantoliverr actually say?
Grant is on his 11th tirzepatide injection, currently at the 7.5mg dose, and reports losing "17 and a half pounds in 10 weeks." He says 7.5mg is "going really well" and that his plan is to "stay on 7.5 for as long as I possibly can" because he wants to "exhaust the dose" before stepping up. He also mentions preferring not to escalate to 10mg before a holiday in five weeks. He invites his audience to share their own losses in the comments as a community moment.
There are no dramatic medical claims here. No cure promises, no dangerous advice, no suggestion that everyone should copy his protocol. This is a personal progress diary filmed in a bathroom. That framing matters when you evaluate what follows.
Does the science back this up?
His weight loss rate is real and consistent with clinical trial data, but it sits at the higher end of what most people experience this early. It is worth understanding what the evidence actually shows before assuming his results are your baseline.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants on tirzepatide 5mg lost a mean of around 15% of body weight over 72 weeks. Early-phase losses tend to be faster. A rate of roughly 1.9 lbs per week in the first 10 weeks is plausible but above average for the general population in trials. Importantly, SURMOUNT-1 was conducted in people with obesity but without type 2 diabetes, which may approximate Grant's context.
His instinct to stay at 7.5mg and avoid unnecessary escalation also has scientific support. Research from Frías et al. (2021, The Lancet) showed dose-dependent efficacy, but some patients achieve meaningful, sustained loss at lower doses without needing to escalate. Staying at a tolerated dose before increasing is a sensible approach consistent with prescribing guidance from NICE and the manufacturer's titration schedule.
What did they get wrong (or right)?
Mostly right, with one thing worth flagging. The concept of "exhausting the dose" is not a formal clinical term, and using it casually on TikTok could give viewers a misleading framework for how tirzepatide works. Dose escalation is driven by tolerability, efficacy plateau, and clinical judgment, not by a fixed idea that you must drain every last unit of effect from one level before moving up.
That said, his underlying instinct is reasonable. Unnecessary escalation increases side effect risk, particularly gastrointestinal symptoms. The SURMOUNT programme data consistently showed that higher doses produced more nausea and vomiting. So while the phrase is imprecise, the behaviour it describes is defensible.
What he gets right is the injection technique discussion. Rotating between left and right abdominal sites is correct practice. Repeated injection into the same spot can cause lipohypertrophy, a localised fat change that reduces drug absorption (Frid et al., 2016, Diabetes Technology and Therapeutics). He stumbled onto good advice even if he did not explain the reason behind it.
What should you actually know?
Three things are worth anchoring here. First, individual weight loss results on tirzepatide vary significantly. SURMOUNT-1 showed a wide distribution around the mean. Grant's 17.5 lbs in 9 weeks is encouraging but not a benchmark. Some people lose less at this stage and still achieve excellent long-term outcomes.
Second, the decision to delay dose escalation before a holiday is pragmatic but should involve your prescriber, not just a personal judgment call. Gastrointestinal side effects from dose increases can be severe enough to disrupt travel, so the logic is sound, but dose management on regulated platforms like this one is a clinical decision, not a lifestyle preference.
Third, the community aspect of this video is genuinely valuable from a behavioural science perspective. Social support and accountability are associated with improved adherence to weight management interventions (Hutchesson et al., 2015, Obesity Reviews). Commenting your losses is not just feel-good content. It may actually help people stay on track.